PL3677266T3 - Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21 - Google Patents

Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21

Info

Publication number
PL3677266T3
PL3677266T3 PL18851555.5T PL18851555T PL3677266T3 PL 3677266 T3 PL3677266 T3 PL 3677266T3 PL 18851555 T PL18851555 T PL 18851555T PL 3677266 T3 PL3677266 T3 PL 3677266T3
Authority
PL
Poland
Prior art keywords
exon
selective inhibitor
mutant egfr
egfr selective
mutant
Prior art date
Application number
PL18851555.5T
Other languages
English (en)
Inventor
Naomi ABE
Shinichi Hasako
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3677266T3 publication Critical patent/PL3677266T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18851555.5T 2017-09-01 2018-08-31 Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21 PL3677266T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017168606 2017-09-01
PCT/JP2018/032314 WO2019045036A1 (ja) 2017-09-01 2018-08-31 エクソン18及び/又はエクソン21変異型egfr選択的阻害剤

Publications (1)

Publication Number Publication Date
PL3677266T3 true PL3677266T3 (pl) 2024-07-01

Family

ID=65527547

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18851555.5T PL3677266T3 (pl) 2017-09-01 2018-08-31 Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21

Country Status (22)

Country Link
US (1) US11701359B2 (pl)
EP (1) EP3677266B1 (pl)
JP (1) JP7065103B2 (pl)
KR (1) KR102676530B1 (pl)
CN (2) CN111465397B (pl)
AU (1) AU2018325819B2 (pl)
CA (2) CA3224526C (pl)
DK (1) DK3677266T5 (pl)
ES (1) ES2972895T3 (pl)
FI (1) FI3677266T3 (pl)
HU (1) HUE066587T2 (pl)
IL (1) IL272929B2 (pl)
JO (1) JOP20200044B1 (pl)
MX (1) MX2020002296A (pl)
MY (1) MY199676A (pl)
PH (1) PH12020500419A1 (pl)
PL (1) PL3677266T3 (pl)
PT (1) PT3677266T (pl)
SG (1) SG11202001861WA (pl)
TW (1) TWI838345B (pl)
WO (1) WO2019045036A1 (pl)
ZA (1) ZA202001445B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017350440B2 (en) 2016-10-31 2023-01-12 Taiho Pharmaceutical Co., Ltd. Selective inhibitor of exon 20 insertion mutant EGFR
FI3677266T3 (fi) 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori
CN113423403B (zh) * 2018-12-28 2025-02-18 大鹏药品工业株式会社 对l718和/或l792突变型治疗有抗性的egfr抑制剂
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
TW202515577A (zh) * 2023-06-27 2025-04-16 日商大鵬藥品工業股份有限公司 患有具有egfr畸變的非小細胞肺癌之個體的治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
WO2006102079A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
SG177306A1 (en) 2009-07-10 2012-02-28 Taiho Pharmaceutical Co Ltd Azabicyclo compound and salt thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2824013A1 (en) 2011-01-07 2012-07-12 Taiho Pharmaceutical Co., Ltd. Novel bicyclic compound or salt thereof
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 1,2,4-トリアジン-6-カルボキサミド誘導体
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
US8889666B2 (en) 2012-02-23 2014-11-18 Taiho Pharmaceutical Co., Ltd. Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
KR20150119401A (ko) 2013-02-22 2015-10-23 다이호야쿠힌고교 가부시키가이샤 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
TWI603971B (zh) 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
JP6583614B2 (ja) 2015-05-11 2019-10-02 大同特殊鋼株式会社 アーク炉の電極折損防止装置
FI3677266T3 (fi) 2017-09-01 2024-03-22 Taiho Pharmaceutical Co Ltd Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori

Also Published As

Publication number Publication date
SG11202001861WA (en) 2020-04-29
CN117159551A (zh) 2023-12-05
IL272929B2 (en) 2024-05-01
JPWO2019045036A1 (ja) 2020-10-15
DK3677266T5 (da) 2024-08-26
KR102676530B1 (ko) 2024-06-20
WO2019045036A1 (ja) 2019-03-07
NZ762195A (en) 2025-08-29
EP3677266A1 (en) 2020-07-08
HUE066587T2 (hu) 2024-08-28
PH12020500419A1 (en) 2021-03-01
AU2018325819A1 (en) 2020-03-19
ES2972895T3 (es) 2024-06-17
CA3224526A1 (en) 2019-03-07
IL272929A (en) 2020-04-30
AU2018325819B2 (en) 2024-02-01
FI3677266T3 (fi) 2024-03-22
RU2020112357A3 (pl) 2022-02-18
MY199676A (en) 2023-11-16
RU2020112357A (ru) 2021-10-04
PT3677266T (pt) 2024-03-04
US11701359B2 (en) 2023-07-18
ZA202001445B (en) 2023-10-25
CA3074418C (en) 2024-04-23
JOP20200044B1 (ar) 2024-04-18
KR20200044918A (ko) 2020-04-29
TWI838345B (zh) 2024-04-11
BR112020004000A2 (pt) 2020-10-20
MX2020002296A (es) 2020-09-10
CN111465397A (zh) 2020-07-28
JP7065103B2 (ja) 2022-05-11
IL272929B1 (en) 2024-01-01
US20200253975A1 (en) 2020-08-13
CA3224526C (en) 2025-07-08
JOP20200044A1 (ar) 2020-02-26
DK3677266T3 (da) 2024-04-22
CN111465397B (zh) 2023-10-13
TW201912160A (zh) 2019-04-01
EP3677266A4 (en) 2021-05-12
EP3677266B1 (en) 2024-01-17
CA3074418A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
HUE066587T2 (hu) Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor
IL266239A (en) Selective inhibitor of egfr with exon 20 insertion mutation
IL280134A (en) Anti-CD112R preparations and methods
ZA202109518B (en) Imidazopyrimidines as eed inhibitors and the use thereof
ZA202002172B (en) Pde9 inhibitor and use thereof
IL282350A (en) Bernani-RGMC inhibitors and their use
SI3720442T1 (sl) Zaviranje mutantnega IDF-1
GB2591554B (en) Composiitons and methods and uses relating thereto
IL269356A (en) Endoscopic measurement methods and tools
IL284330A (en) Treatment-resistant EGFR inhibitor mutant L718 and/or L792
SG11202104448WA (en) Compositions and methods
GB201817444D0 (en) Methods and compositions
PL4011898T3 (pl) Pochodna 3-hydroksy-5-pregnan-20-onu i jej zastosowanie
GB2590329B (en) Drilling systems and methods
GB2612726B (en) Drilling systems and methods
GB201819987D0 (en) Methods and compositions
GB201906169D0 (en) Drilling systems and methods
GB201804092D0 (en) Methods and compositions
GB2594831B (en) Rheometer systems and related methods
IL269723A (en) Mixtures containing mutant alpha-1-antitrypsin and their use
IL276476B2 (en) Crystalline EGFR inhibitor and its uses
GB2579366B (en) Drilling systems and methods
GB201902266D0 (en) New methods and uses
GB202101948D0 (en) Drilling systems and methods
GB201812776D0 (en) New methods and uses